Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) – Oppenheimer issued their Q1 2023 EPS estimates for shares of Aldeyra Therapeutics in a report issued on Thursday, March 9th. Oppenheimer analyst J. Kim expects that the biotechnology company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($1.38) per share. Oppenheimer also issued estimates for Aldeyra Therapeutics’ Q2 2023 earnings at ($0.30) EPS, Q3 2023 earnings at ($0.34) EPS and Q4 2023 earnings at ($0.30) EPS.
Several other brokerages have also recently issued reports on ALDX. StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, November 14th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, March 1st. Finally, Citigroup boosted their target price on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research report on Friday.
Aldeyra Therapeutics Trading Down 9.1 %
Hedge Funds Weigh In On Aldeyra Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ALDX. Knoll Capital Management LLC raised its position in Aldeyra Therapeutics by 24.9% in the third quarter. Knoll Capital Management LLC now owns 1,877,305 shares of the biotechnology company’s stock worth $10,025,000 after acquiring an additional 374,845 shares in the last quarter. Woodstock Corp raised its holdings in shares of Aldeyra Therapeutics by 23.3% in the 3rd quarter. Woodstock Corp now owns 129,179 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 24,445 shares during the period. Virtu Financial LLC purchased a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at about $99,000. International Assets Investment Management LLC raised its holdings in shares of Aldeyra Therapeutics by 4.8% during the 2nd quarter. International Assets Investment Management LLC now owns 59,875 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 2,750 shares during the period. Finally, Jump Financial LLC purchased a new stake in Aldeyra Therapeutics during the 3rd quarter worth approximately $267,000. 63.11% of the stock is owned by institutional investors and hedge funds.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
- Get a free copy of the StockNews.com research report on Aldeyra Therapeutics (ALDX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.